Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): A polymeric derivative of camptothecin (CPT)

British Journal of Cancer

Volumn 91, Issue 1, 2004, Pages 50-55

  Bissett, D ^a,e   Cassidy, J ^a   De Bono, J S ^b   Muirhead, F ^b   Main, H ^a   Robson, L ^c   Fraier, D ^d   Magne M L ^d   Pellizzoni, C ^d   Porro, M G ^d   Spinelli, R ^d   Speed, W ^d   Twelves, C ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d PFIZER INC   (United States)

^e ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

Camptothecin; MAG CPT; Pharmacokinetics; Polymeric

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; COPOLYMER; FLUOROURACIL; FOLINIC ACID; PNU 166148; UNCLASSIFIED DRUG; ACRYLAMIDE DERIVATIVE; CAMPTOTHECIN; DRUG DERIVATIVE; POLY(1 METHACRYLOYLAMIDO 2 HYDROXYPROPANE CO 20 O (METHACRYLOYLGLYCYL 6 AMINOHEXANOYLGLYCYL)); POLY(1-METHACRYLOYLAMIDO-2-HYDROXYPROPANE-CO-20-O-(METHACRYLOYLGLYCYL-6-AMINOHEXANOYLGLYCYL));

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG RELEASE; DRUG TOLERANCE; DRUG URINE LEVEL; FEMALE; HEMATOLOGIC DISEASE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MALE; MALIGNANT MESOTHELIOMA; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; CHEMICALLY INDUCED DISORDER; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; NEOPLASM;

ACRYLAMIDES; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DIARRHEA; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; SEPSIS; THROMBOCYTOPENIA;

EID: 3342969698     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601922     Document Type: Article

References (13)

1. Caiolfa VR, Zamai M, Fiorino A, Frigerio E, Pellizzoni C, D'Argy R, Ghiglieri A, Castelli MG, Farao M, Pesenti E, Gigli M, Angelucci F, Suarato A (2000) Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. J Control Release 65: 105-119
2. Conover CD, Greenwald RB, Pendri A, Gilbert CW, Shum KL (1998) Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker. Cancer Chemother Pharmacol 42: 407-414
3. Conover CD, Greenwald RB, Pendri A, Shum KL (1999) Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs. Anticancer Drug Des 14: 499-506
4. Duncan R, Gac-Breton S, Keane R, Musila R, Sat YN, Satchi R, Searle F (2001) Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. J Control Release 74: 135-146
5. Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB (1970) Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54: 461-470
6. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46: 6387-6392
7. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS (1972) Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 56: 515-521
8. Rivory LP, Robert J (1995) Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives. Pharmacol Ther 68: 269-296
9. Sarapa N, Brillo MR, Speed W, Jannuzzo M, Breda M, James CA, Porro M, Rocchetti M, Wanders A, Mahteme H, Nygren P (2003) Assessment of normal and tumor tissue uptake of MAC-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma. Cancer Chemother Pharmacol 52: 424-430
10. Schoemaker NE, Frigerio E, Fraier D, Schellens JH, Rosing H, Jansen S, Beijnen JH (2001) High-performance liquid chromatographic analysis for the determination of a novel polymer-bound camptothecin derivative (MAG-camptothecin) and free camptothecin in human plasma. J Chromatogr B 763: 173-183
11. Schoemaker NE, van Kesteren C, Rosing H, Jansen S, Swart M, Lieverst J, Fraier D, Breda M, Pellizzoni C, Spinelli R, Grazia PM, Beijnen JH, Schellens JH, Bokkel Huinink WW (2002) A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. Br J Cancer 87: 608-614
12. Seymour LW (1992) Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Systems 9: 135-187
13. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E, Cassidy J (1999) Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 5: 83-94